Uusi Cleveland Clinic -tutkimus osoittaa ensimmäistä kertaa, että FDA: n hyväksymä ibrutinibi (ibrutinibi) lymfoomalle ja leukemialle voi myös auttaa hoitamaan yleisimpiä ja tappavimpia aivokasvaimia, ja sitä voidaan käyttää yhtenä päivänä glioblastoomapotilaille ja parantaa selviytymisastetta.
American Brain Tumor Associationin raportin mukaan glioblastooman eloonjäämisaste on hyvin alhainen, ja tavanomaista hoitoa saavien potilaiden mediaani eloonjäämisaika on alle 15 kuukautta. Glioblastoma on kuolettavin primaarinen aivokasvain ja on erittäin vastustuskykyinen nykyisille hoidoille. Näille potilaille on kiireellisesti annettava uusia hoitoja mahdollisimman pian.
In an earlier study, Bao and colleagues found that gliooma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain kasvaimet in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
